Technology | Drug-Eluting Balloons | July 26, 2017

FDA Clears Spectranetics Stellarex Drug-Coated Balloon

Stellarex produces top-tier clinical outcomes with a low drug dosage for patients with peripheral arterial disease

Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon

July 26, 2017 — The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the Stellarex drug-coated balloon (DCB). The device is designed to restore and maintain blood flow to the superficial femoral and popliteal arteries in patients with peripheral arterial disease (PAD).

This is the third drug-coated balloon to gain FDA clearance, joining the previously cleared Medtronic In-Pact Admiral and the C.R. Bard Lutonix. Read about the first FDA approvals in the article “Drug-eluting Balloons Enter the U.S. Market.”

The Stellarex DCB has shown safety and efficacy in a cohort of patients which included a higher preponderance of diabetics and core-lab defined severely calcified lesions in the U.S. investigational device exemption (IDE) trial. These results, in combination with the cohort of patients studied in the European Randomized Controlled Trial, demonstrate the Stellarex DCB is safe and effective in diverse patient populations when addressing symptomatic femoropopliteal disease,” stated Prakash Krishnan, M.D., ILLUMENATE Pivotal Trial’s co-principal investigator, Mount Sinai in New York.

Sean Lyden, M.D., ILLUMENATE Pivotal Trial’s co-principal investigator, Cleveland Clinic, Cleveland, Ohio added, “The ILLUMENATE Pivotal Trial treated a challenging patient population with a low paclitaxel drug dose. When considering options, I think most clinicians would prefer to use a lower drug dose if they can also achieve great patency results.”

Throughout the ILLUMENATE Trial Series, the Stellarex DCB’s EnduraCoat Technology demonstrates both safety and efficacy with consistently high patency rates and low clinically driven target lesion revascularization rates in a range of lesion complexities and patient co-morbidities. The device offers both hybrid paclitaxel crystallinity and a durable excipient to provide efficient drug transfer, effective drug residency with high coating durability and minimal particulate loss.

There are five ILLUMENATE clinical studies evaluating the safety and efficacy of the Stellarex DCB platform and supporting United States regulatory filings:

  • The ILLUMENATE EU Randomized Study is a prospective, randomized controlled, multi-center trial with 328 patients.  The primary safety and effectiveness endpoints at 12 months were met and superiority over percutaneous transluminal angioplasty (PTA) was demonstrated in both. The 12-month primary patency rate was 83.9 percent (188/224) in the Stellarex arm vs. 60.6 percent (40/66) in the PTA arm (P<0.001), per Kaplan Meier (KM) estimate the patency rate at day 365 was 89 percent vs. 65 percent, respectively (log-rank p<0.001);
  • The ILLUMENATE Pivotal Study is a prospective, randomized controlled, multi-center trial with 300 patients enrolled. The cohorts were well match and included a preponderance of patients with diabetes (50 percent) and severely calcified lesions (44 percent). The primary safety and effectiveness endpoints at 12 months were met and superiority over PTA was demonstrated in both. The primary patency rate was significantly higher in the Stellarex group at 76.3 percent (135/177) vs. 57.6 percent (53/92) for PTA (p=0.003). The 12-month primary patency rate, per KM estimate at day 365 was 82.3 percent in the DCB arm vs. 70.9 percent in the PTA arm (p=0.002);
  • The ILLUMENATE Global Study is a prospective, multi-center, single-arm study with 371 patients enrolled. The 12-month primary patency rate was 81.4 percent per KM estimate;
  • The ILLUMENATE First-In-Human (FIH) Study was a non-randomized, multi-center study that enrolled 80 patients. In the pre-dilatation arm (n=50), the primary patency rate per KM estimate was 89.5 percent at 12 months and 80.3 percent at 24 months; and
  • The ILLUMENATE Pharmacokinetic Study measured the paclitaxel drug levels in the blood of 25 patients and showed all patients had detectable paclitaxel levels after DCB deployment that declined rapidly within the first hour (54.4±116.9 ng/mL to 1.4±1.0 ng/mL).

Covidien originally developed the Stellarex and gained European CE mark approval in January 2015. In 2015, Covidien sold the Stellarex DCB platform to Spectranetics.  Spectranetics received Eurpean CE mark approval for a 0.014-inch version of the device in late 2016.

 

Watch the VIDEO “Drug-coated Balloons Enter the U.S. Market,” and interview with Doug Drachman, M.D., Mass General Hospital, who served a the site principal investigator for the Lutonix balloon trial.

 

For more information: www.spectranetics.com

Related Content

CorInnova Awarded 2017 InnoSTARS Prize for EpicHeart Soft Robotic Heart Assist Device
News | Artificial Heart| December 11, 2017
CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science competition for its...
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Robocath Receives $1.5 Million in Capital for Advancement of R-One Robotic System
News | Robotic Systems| December 06, 2017
December 6, 2017 — French company Robocath, which designs and develops...
New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

Feature | December 06, 2017 | Dave Fornell
Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magaz
New Tool Predicts Risk of Heart Attack in Older Surgery Patients
News | Cardiac Diagnostics| December 05, 2017
A tool designed to more accurately predict the risk of heart attack in older patients undergoing non-cardiac surgery...
Toshiba Medical Rolls Out Interactive Learning Tools for Ultrasound and Vascular Training
News | Ultrasound Imaging| December 04, 2017
Toshiba Medical, a Canon Group company, introduced new educational tools and interactive learning resources to help...
Philips Azurion Platform Improves Clinical Workflow and Staff Experience Benefits
News | Angiography| December 04, 2017
Philips recently announced the results of a comprehensive, independent, two-year study demonstrating the clinical...
Studies find 15 percent of all heart attack and stroke patients and 9 percent of CABG patients were uninsured before passage of the Affordable Care Act. AHA 2017, #aha2017
News | November 25, 2017
November 25, 2017 — The majority of patients without health insurance who were hospitalized for heart attack, stroke
The Corvia intra-atrial shunt to treat diastolic heart failure.

The Corvia intra-atrial shunt to treat diastolic heart failure.

Feature | Heart Failure| November 25, 2017
November 25, 2017 – Results presented at the 2017 American Heart Association (AHA) Scientific Sessions and published
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init